TransMedics Group, Inc.·4

May 22, 4:15 PM ET

TOBIN JAMES R 4

4 · TransMedics Group, Inc. · Filed May 22, 2026

Research Summary

AI-generated summary of this filing

Updated

TransMedics (TMDX) Director James R. Tobin Receives 2,922 RSU Award

What Happened James R. Tobin, a director of TransMedics Group, Inc. (TMDX), was granted 2,922 restricted stock units (RSUs) on May 20, 2026. The Form 4 reports an acquisition type "A" at $0.00 per unit (total reported acquisition value $0). Each RSU is a contingent right to receive one share of TransMedics common stock.

Key Details

  • Transaction date: 2026-05-20; Form 4 filed 2026-05-22 (appears timely).
  • Security: 2,922 RSUs granted, reported acquisition price $0.00; total reported value $0.
  • Footnote: RSUs consist of contingent rights to receive one share each (vesting terms not specified in the filing).
  • Shares owned after transaction: not specified in the supplied filing details.
  • Transaction code: A = Award/Grant (not a market purchase or sale).

Context RSU grants are typically compensation awards and do not represent an immediate cash purchase or sale; they generally convert to shares only if and when vesting conditions are met. The $0 acquisition price on the Form 4 reflects grant accounting, not market value—market exposure occurs only upon vesting and delivery of shares.

Insider Transaction Report

Form 4
Period: 2026-05-20
Transactions
  • Award

    Common Stock

    [F1]
    2026-05-20+2,9226,981 total
Holdings
  • Common Stock

    (indirect: By Trust)
    155,146
  • Common Stock

    (indirect: By Trust)
    18,000
Footnotes (1)
  • [F1]Consists of 2,922 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.
Signature
By: /s/ Gerardo Hernandez, Attorney-in-Fact|2026-05-22

Documents

1 file
  • 4
    ownership.xmlPrimary

    4